The largest whole-genome sequencing study thus far has revealed myriad actionable alterations and potential biomarkers for 33 cancer types, but various logistical, technical and economic challenges must be overcome before this technique can become standard of care.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Aaltonen, L. A. et al. Nature 578, 82–93 (2020).
Sosinsky, A. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02682-0 (2023).
Sosinsky, A. et al. Ann. Oncol. 30, vii1 (2019).
Austin-Tse, C. A. et al. Genomic Med. 7, 27 (2022).
Cheng, D. T. et al. J. Mol. Diagn. 17, 251–264 (2015).
Dorschner, M. O. et al. Am. J. Hum. Genet. 93, 631–640 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Akhoundova, D., Rubin, M.A. The grand challenge of moving cancer whole-genome sequencing into the clinic. Nat Med 30, 39–40 (2024). https://doi.org/10.1038/s41591-023-02697-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02697-7